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We have developed a bilayered dermal–epidermal scaffold for application in the treatment of full-thick-
ness skin defects. The dermal component gels in situ and adapts to the lesion shape, delivering human
dermal ﬁbroblasts in a matrix of ﬁbrin and cross-linked hyaluronic acid modiﬁed with a cell adhesion-
promoting peptide. Fibroblasts were able to form a tridimensional matrix due to material features such
as tailored mechanical properties, presence of protease-degradable elements and cell-binding ligands.
The epidermal component is a robust membrane containing cross-linked hyaluronic acid and poly-
L-lysine, on which keratinocytes were able to attach and to form a monolayer. Amine–aldehyde bonding
at the interface between the two components allows the formation of a tightly bound composite scaffold.
Both parts of the scaffold were designed to provide cell-type-speciﬁc cues to allow for cell proliferation
and form a construct that mimics the skin environment.
 2014 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.1. Introduction
Adult skin is composed of the epidermis and dermis: the top
layer of the epidermis is the stratum corneum, a thin, water-tight
layer of dead, ﬂattened cells covering rapidly dividing keratino-
cytes beneath. The underlying thicker dermis is a complex associ-
ation of ﬁbroblasts, blood vessels, nerve ﬁbers and lymphatics
embedded in the extracellular matrix (ECM) [1,2]. The dermis
and epidermis are connected by the dermal–epidermal junction,
which is composed of the basal cell plasma membrane, a multilay-
ered structure which contains hemidesmosomes and which
provides epidermal–dermal adherence and mechanical support
for the epidermis, and acts as a barrier to the transfer of cells
and of some large molecules across the junction [3]. Skin injury
from thermal trauma and other causes is an important public
health problem [4]; third-degree burns, which involve damage to
epidermal, dermal and deeper layers, cause the hospitalization ofhundreds of thousands of patients every year [5]. In full-thickness
defects, particularly in lesions more than 4 cm across and 0.4 mm
deep, natural healing is inadequate due to a lack of remaining regen-
erative elements [1,6–8], and grafting of skin is likely to be neces-
sary [6]. Common skin grafting techniques involve transplanting
split-thickness skin [9], which contains the epidermis and a
variable fraction of the underlying dermis. The availability of donor
skin is a limiting factor requiring the development of engineered
dermo-epidermal skin substitutes analogous to full-thickness
autologous skin [9].
Extant commercially available skin substitutes have limitations.
The only commercially available bilayered scaffold skin substitute
(combination of Laserskin and Hyalograft3-D™) requires multiple
procedures [4,10–12]. Collagen-based skin substitutes containing
dermal ﬁbroblasts and keratinocytes suffer from limited anchorage
and keratinocyte survival, poor structural integrity and incomplete
cell differentiation [13,14].
Patients could beneﬁt greatly from a scaffold which mimics the
two-compartment structure of skin and that could be easily han-
dled and applied, rapidly adapting to complex three-dimensional
lesion sites and composed of materials that promote angiogenesis
(ﬁbrin [15–17] and hyaluronic acid [18]). Such scaffolds should be
applicable to any depth or shape of lesion, and should allow the
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properties for each compartment, speeding up the healing process
by the simultaneous regeneration of dermis and epidermis [13,19].
We have designed an in situ forming dermal–epidermal scaffold
which is adaptable to differing lesion shapes, and is designed to
mimic the bilayer structure of human skin while providing instruc-
tive cues for cell adhesion, migration and proliferation. The dermal
component consists of ﬁbrin and cross-linked hyaluronic acid
(HAX), modiﬁed with a peptide derived from the cell adhesion
molecule ﬁbronectin to improve cell attachment. The dermal layer
provides a porous, proteolytically degradable bioactive scaffold
where dermal ﬁbroblasts can proliferate and form a tridimensional
matrix. The epidermal component is a mechanically robust
membrane of HAX combined with poly-L-lysine (PLL) to provide
anchoring to the dermal layer via aldehyde–amine interactions
and coated by laminin-5 to enhance the attachment of keratino-
cytes (Fig. 1). In a clinical context, the dermal hydrogel withFig. 1. Schematic of the bilayered epidermal–dermal scaffold. (A) An in situ gelling derm
lesion and adapts to its shape. (B) A thin epidermal membrane pre-seeded with keratino
green) interacts with positively charged PLL in the membrane (pink). (C) The epidermal
the epidermal component (pink) react with aldehydes in the dermal component (blue) to
single composite scaffold.ﬁbroblasts would be injected into the lesion, crosslinking in situ
and adapting to the lesion shape in seconds, with immediate sub-
sequent application of the epidermal membrane seeded with
keratinocytes on the top surface. The free aldehyde groups of the
dermal hydrogel would react covalently with amines of the PLL-
modiﬁed epidermal hyaluronic acid (HA) membrane layer to create
a single structure in situ.
2. Materials and methods
2.1. Materials
Sodium hyaluronate (MW 351–600 kDa and 1.2–1.8 MDa) was
purchased from LifeCore Biomedical (Chaska, MN, USA). Adipic
acid dihydrazide (ADH), 1-ethyl-3-[3-(dimethylamino)-propyl]car-
bodiimide (EDC), sodium hydroxide, hydrochloric acid, hydroxy-
benzotriazole, sodium periodate, ethylene glycol, Dowexal component (blue) containing human dermal ﬁbroblasts (green) is applied into the
cytes is applied on top of the dermal layer. Inset: negatively charged laminin (light
layer protects the dermal part from dehydration and infection. Inset: free amines of
form covalent imine interactions which glue the two components together to form a
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diamidino-2-phenylindole (DAPI), phalloidin, poly-L-lysine (PLL;
MW 4000–15,000 Da), ﬂuorescein isothiocyanate (FITC)-labeled
PLL (MW 30–70 kDa), thrombin (300 NIH units mg1), ﬁbrinogen
from human plasma, anhydrous N,N-dimethylformamide (99.8%),
paraformaldehyde (PFA), hyaluronidase and Triton™ X-100 were
obtained from Sigma (St. Louis, MO, USA). Dialysis membranes
(MW cutoff 3.5 kDa) were purchased from Spectrum Labs
(Rancho Dominguez, CA, USA). The ﬁbronectin active fragment,
Gly–Arg–Gly–Asp–Ser, was purchased from Peptides International
(Louisville, KY, USA). Laminin-5 protein, mouse monoclonal to
cytokeratin 14 and goat polyclonal secondary antibody to mouse
IgG (H&L) (FITC) were obtained from Abcam (Cambridge, MA,
USA). Amicon centrifugal ﬁlter units, Transwell with 3.0 lm
pores and Millicell cell culture polycarbonate inserts with
0.4 lm pores, 12 mm ﬁlter diameter, were obtained from Millipore
(Billerica, MA, USA). Biopsy punches were obtained from
HealthLink (Jacksonville, FL, USA). A cell strainer with a 100 lm
pore size was purchased from BD Biosciences (Franklin Lakes, NJ,
USA). Alexa Fluor-647 hydrazide, LIVE/DEAD assay, alamarBlue
assay, Quant-iT™ PicoGreen dsDNA kit, phosphate-buffered
saline (PBS), human keratinocytes and human ﬁbroblasts, Dul-
becco’s modiﬁed Eagle’s medium (DMEM), fetal bovine serum
(FBS) and penicillin–streptomycin (Pen/Strept) were obtained from
Invitrogen Life Technologies (Carlsbad, CA, USA). Progenitor cell
target medium (CnT-57) was obtained from CELLnTEC (Bern,
Switzerland). Double-barrel syringes were obtained from Baxter
(Deerﬁeld, IL, USA). Polytetraﬂuoroethylene (Teﬂon) molds were
obtained from VWR International (Chicago, IL, USA).
2.2. Cell culture
Human keratinocytes were expanded in CnT-57 medium sup-
plemented with 1% Pen/Strept. Fourth passage keratinocytes were
used in experiments. Human primary skin ﬁbroblasts were
expanded in DMEM supplemented with 10% FBS and 1% Pen/Strep.
Fibroblasts used for experiments were at passage three. Cells were
passaged using standard protocols and cultured in a 5% CO2 incu-
bator at 37 C.
2.3. HA modiﬁcation
High MW HA (1.2–1.8 MDa) and low MW HA (351–600 kDa)
were functionalized respectively with aldehyde (HA-CHO) and
hydrazide (HA-ADH) groups, as described previously [20,21]. The
HA modiﬁcation into HA-CHO or HA-ADH was conﬁrmed using
proton nuclear magnetic resonance (1H NMR).
2.4. Activation of HA-CHO by the ﬁbronectin active fragment
Prior to modiﬁcation with the ﬁbronectin active fragment,
HA-CHO polymer was ion exchanged overnight in Dowex 50 W
X8-400 resin. For this, 40 mg of the HA-CHO was dissolved in
PBS. The carboxylic acid group on HA-CHO was activated by
S-NHS (3 equivalents). The reaction was mediated by ECD-HCl
(3 equiv) for 30 min. After ﬁltration using Amicon units (MW
cutoff 10 kDa), 5 mg of the cell adhesion peptide ﬁbronectin active
fragment (MW 490.47 Da), was conjugated to the activated
HA-CHO through amide bond formation. After the reaction, the
HA-GRGDS solution was puriﬁed by exhaustive dialysis (MW
cutoff 3.5 kDa), frozen in liquid nitrogen and lyophilized.
The change in the molecular weight from the HA-CHO to the
HA-CHO-GRGDS was veriﬁed by gel permeation chromatography
(GPC). The degree of peptide modiﬁcation per available carboxylic
acid was determined by 1H NMR.2.5. Preparation of the dermal component for ﬁbroblast culture
Solutions of HA-CHO-GRGDS (40 mg ml1), thrombin
(6.25 mg ml1, 300 NIH units mg1), HA-ADH (40 mg ml1) and
ﬁbrinogen (83.4 mg ml1) were prepared in DMEM containing
10% FBS. Two independent mixtures were created: (i) 200 ll of
HA-CHO-GRGDS (40 mg ml1) was mixed with 200 ll thrombin;
and (ii) 200,000 human ﬁbroblasts in 200 ll of the HA-ADH
(40 mg ml1) were mixed with 200 ll ﬁbrinogen. A double-barrel
syringe was used to mix the solutions and the formed gel was
poured in a 48-well plate.
2.6. Gelation time of the dermal component
Equal volumes (200 ll) of the HA-CHO-GRGDS-thrombin and
the HA-ADH-ﬁbrinogen were mixed and stirred in a glass vial with
a stirring bar until formation of a solid gel (the dermal component).
The gelation time was deﬁned as the time required to create the
solid globule, which was completely separated from the bottom
of three glass vials.
2.7. Degradation studies
Degradation studies were carried out by incubating four sam-
ples of the dermal hydrogel (after reaching the swelling equilib-
rium) in PBS, in the presence of 10 U ml1 hyaluronidase, in an
orbital shaker at 37 C. Samples were placed in transwells to facil-
itate handling. Every day, they were blotted dry and weighed, and
the hyaluronidase solution was replaced. The percentage of weight
loss was determined by dividing the measured weight at each time
point (Wt) by the initial weight after swelling to equilibrium in PBS
(Wi): % weight =Wt/Wi  100. Scanning electron microscopy (SEM)
images of the samples were obtained after freeze-drying.
2.8. SEM and pore size determination
The morphology of the freeze-dried samples was observed
under a 5600LV scanning electron microscope (JEOL, Tokyo, Japan),
after sputter-coating them with an ultrathin (10 nm) layer of gold
using a Hummer 6.2 Sputtering System from Anatech Ltd (Hay-
ward, CA, USA). The pore size was determined using the mea-
sure-length function in the AxioVision Software (Zeiss, Germany).
When the pores were not exactly round, the length was measured
as the greatest diameter in each pore.
2.9. Determination of the mechanical properties of the dermal
component
The viscoelastic shear properties of the gels HAX-GRGDS, ﬁbrin/
HAX-GRGDS and ﬁbrin were measured at low frequencies using an
AR-2000 rheometer (TA Instruments, Inc., New Castle, Delaware,
USA). Samples were fully swollen in PBS prior to measurements.
A plate-and-plate (parallel plate) geometry was used to apply
oscillatory shear to hydrogel samples using a stainless steel plate
(20 mm diameter) at 25 C. Gel disks (1 ml total volume) were
made in a 12-well plate and then cut with a 12 mm biopsy punch.
The fully swollen gels were placed between the two plates so that a
gap of 1000 or 1800 lm was maintained between the two plates.
Strain sweep tests were done to ensure that the shear property
measurements were done in the linear region of the stress–strain
curve. The viscoelastic shear properties are independent of the
strain applied in the linear region. A target shear strain value
was identiﬁed by measuring the viscoelastic shear properties as a
function of strain applied (0.6% strain was used to measure the
shear properties). Measurements of the shear properties were then
made by systematically varying the frequency from 1 to 10 Hz. The
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mechanical properties of the hydrogels used in this study.2.10. Preparation of the epidermal component for keratinocytes’
culture
HA-CHO (40 mg ml1 in PBS) and HA-ADH (40 mg ml1 in PBS)
were mixed with a PLL solution (1 mg ml1) at an experimentally
optimized ratio of 2:2:1 and poured into a polytetraﬂuoroethylene
(Teﬂon) mold. Because HA is a polyanion and PLL is a polycation,
its complexation, followed by the solvent evaporation at room
temperature (RT), allowed the creation of a stable membrane. After
drying, the membrane easily detached from the mold surface. For
further surface modiﬁcation with (FITC-labeled)-PLL, they were
immersed in a solution of 11 mg ml1 S-NHS, 50 mg ml1 EDC-
HCl and 5 mgml1 (FITC-labeled)-PLL, and left to react for 18 h.
After thorough washing with PBS, a 8 mm diameter biopsy punch
was used to create small membranes. For cell culture, these mem-
branes were coated with laminin-5 (1 lg ml1) and left overnight
in the humidiﬁed incubator. The membranes were placed in cell
culture porous inserts. The next day, 1  105 keratinocytes in
400 ll of CnT-57 medium were seeded into the membranes.2.11. Force measurements of the epidermal component
Young’s modulus was measured using an atomic force micro-
scope (Model MFP-3-D, Asylum Research, Santa Barbara, CA,
USA) with an antimony-doped silicon cantilever (f0 = 50–100 kHz,
k = 1–5 N m1; Model FESP, Bruker AFM Probes, Camarillo, CA,
USA). Data were collected and analyzed using a proprietary proce-
dure running in Igor Pro software (WaveMetrics, Inc., Portland OR,
USA). Hydrogel samples were clamped onto a glass slide and sub-
merged in PBS. Force curves were collected in contact mode.
Young’s modulus was calculated by ﬁtting the linear portion of
force curves with the Hertz model.2.12. Adhesion studies
As a preliminary study to assess the adhesion between the epi-
dermal and the dermal layer, 8 mg of the HA-CHO was reacted
with 0.48 mg Alexa Fluor-647 hydrazide in a PBS buffer for 4 h
at RT. The HA-Alexa Fluor-647 conjugate was then puriﬁed by
dialysis (MW cutoff 30 kDa) for 2 days. To create a green ﬂuores-
cent membrane, 30% PLL was replaced by FITC-labeled polymer
to prepare the epidermal membrane.
In order to quantify the adhesion, a 12 mm biopsy punch was
used to cut both the membrane and the dermal substitute. Mem-
branes containing the PLL modiﬁcation or not and the dermal sub-
stitutes were glued separately with Super Glue to 14 mm metal
tubular ﬁttings, providing a ﬂat and stable presentation. The tubu-
lar ﬁttings were inserted into the upper and lower arms of the
mechanical testing apparatus Instron (Norwood, MA, USA) conﬁg-
ured for tensile testing, with the membranes and the gels facing
each other. The membranes were kept in contact with the dermal
component for 10 min under a 1.3 N setting force in order to cure.
The tissue–adhesive interface was displaced at a rate of
0.05 mmmin1 until complete separation occurred. The maximal
force measured by the 20 N load cell prior to interface failure
was recorded as the adhesion force of the tested material. To test
if covalent bonding of aldehydes in the dermal component with
amines of the epidermal component increased the force required
to separate the two layers, we blocked aldehyde groups with adipic
acid dihydrazide (5 mg ml1) for 15 min prior to the experiment.2.13. alamarBlue assay
The alamarBlue proliferation assay was performed according
to the manufacturer’s instructions [22]. Brieﬂy, the stock solution
was diluted in cell culture medium at a 1:10 ratio, then 1 ml of this
solution was added to the scaffolds in a 48-well plate and incu-
bated for 4 h at 37 C in the dark. Next, 100 ll of this solution
was transferred into a 96-well plate and the ﬂuorescence was read
at 600 nm using excitation at 570 nm. The background ﬂuores-
cence was subtracted from all values.2.14. DNA quantiﬁcation
Cellular DNA was quantiﬁed using the PicoGreen dsDNA kit,
according to the manufacturer instructions [23]. The cell content
was removed from the scaffolds by freezing them at 80 C and
subsequent sonication. The ﬂuorescence of samples and standards
was measured using 485 nm excitation light at an emission wave-
length of 528 nm. The DNA concentration was extrapolated from a
previously established standard curve.2.15. LIVE/DEAD assay
The LIVE/DEAD cell viability kit for mammalian cells [24] was
used to visualize cell viability after different periods of culture. Cal-
cein-AM and ethidium homodimer-1 were dissolved in PBS at con-
centrations of 2 and 4 lM, respectively. Keratinocytes and
ﬁbroblast were incubated with this solution for 20 min. After
washing twice with PBS, the ﬂuorescence of the cells was observed
using a Zeiss 710 confocal microscope (Germany).2.16. Immunocytochemistry
For immunocytochemistry, cells were ﬁxed overnight at 4 C in
4% PFA dissolved in PBS. After washing twice with PBS, cells were
permeabilized using 0.25% Triton™ X-100. In order to block non-
speciﬁc antibody binding, cells were incubated for 30 min at RT
with 1% BSA in PBS. The BSA solution was removed and the cells
were incubated in cytokeratin-14 (1:400) overnight at 4 C. After
washing three times with PBS, the secondary antibody goat poly-
clonal secondary antibody to mouse IgG (H&L) (FITC) was added
in the concentration 1:4000. After washing three times, the actin
ﬁlaments were stained with phalloidin (1:200) for 20 min at RT
and the cell nuclei were stained with DAPI (0.1 lg ml1) for
1 min, also at RT. Cells were then observed under a ﬂuorescence
microscope (Zeiss, Germany).2.17. Histology
Samples with cells were ﬁxed in 4% PFA overnight at 4 C and
left in 70% ethanol. Specimens were embedded in parafﬁn wax
and sectioned into 6 lm sections, which were routinely processed
for hematoxylin and eosin staining (H&E).2.18. Data analysis
Experiments were performed using four samples per condition.
Data are presented as mean ± standard deviations, with n = 4 for
each group, compared by one-way analysis of variance and Tukey’s
post hoc multiple comparison test or by an unpaired t-test using
GraphPad Prism 5 software (La Jolla, CA, USA).
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We have developed an epidermal–dermal skin substitute com-
posed of (i) an in situ gelling dermal component, which adapts to
the shape of the lesion, and (ii) an epidermal component, which
anchors to and protects the dermal component. The dermal substi-
tute contains human dermal ﬁbroblasts three-dimensionally dis-
tributed in a ﬁbrin/HAX-GRGDS gel. The epidermal substitute is a
membrane composed of HAX and PLL, which anchors to the dermal
component via aldehyde–amine crosslinking, forming a single
composite structure (Fig. 1).
3.1. Dermal component
A composite hydrogel providing appropriate mechanical prop-
erties, protease-degradable elements and cell-binding ligands
was designed to mimic the dynamic network of the dermal ECM,
consisting of protein ﬁbers and polysaccharides [25,26]. HA was
chosen as the polymeric basis for the scaffold matrix because it
is biodegradable, and promotes migration, differentiation and pro-
liferation of ﬁbroblasts and endothelial cells [27,28]. HA enhances
angiogenesis and the production of ECM components during
wound healing, supporting regeneration and the scarless healing
of wounds [29,30]. Despite these useful properties, cells do not eas-
ily attach to HA, because of its hydrophilicity [31–33]. Conjugation
of RGD peptides can improve cell adhesion to HA [34].
We modiﬁed the HA polymer for the dermal component with
the ﬁbronectin-derived peptide GRGDS [35–37] (Fig. 2A). The suc-
cessful conjugation of the peptide sequence to the activated car-
boxylic acid of the aldehyde modiﬁed HA (HA-CHO, to be reacted
with HA-ADH in order to form HAX) was conﬁrmed by NMRFig. 2. Peptide conjugation to HA-CHO. (A) Chemical structure of HA-CHO, the ﬁbronect
denotes methylene protons in the side chains of arginine and aspartate in the GRGDS pep
methyl protons of HA-CHO at 1.8 ppm). (B) 1H-NMR spectra showing that approximately
the conjugated peptide). (C) GPC showing an increase in molecular weight of the HA-CH(Fig. 2B) and by gel permeation chromatography (Fig. 2C).
Comparison of the integrated 1H NMR signals of the methyl
protons of HA-CHO (chemical shift 1.8 ppm in NMR spectrum)
with the methylene protons on the side chains of arginine (R)
and aspartic acid (D) in the GRGDS peptide (chemical shift at
2.6–2.8 ppm in spectrum) showed that the degree of HA
carboxylic acid modiﬁcation with the peptide was approximately
10%. The modiﬁcation of HA-CHO with GRGDS decreased its
retention time on GPC, indicating that its molecular weight was
increased (Fig. 2C). The peak did not broaden and there were no
detectable new peaks with shorter retention times, suggesting that
the dispersity of the polymer did not change signiﬁcantly and that
no detectable amounts of high-molecular-weight cross-linked
polymer products resulted from the conjugation reaction.
HA was also modiﬁed with adipic hydrazide (HA-ADH), to allow
in situ cross-linking with HA-CHO (forming cross-linked HA, HAX)
upon application with a double-barrel syringe. Both HA-CHO and
HA-ADH were modiﬁed using established protocols [38–40]. The
degree of ADH incorporation in HA was veriﬁed by 1H NMR spec-
troscopy and the percentage of oxidation of HA was quantiﬁed
by measuring the number of aldehyde groups in the polymer using
t-butyl carbazate [20,41,42].
Fibrin (formed from the reaction of ﬁbrinogen with thrombin)
was incorporated into the dermal component to confer protease
degradability [43,44] and to modulate gel stiffness in order to facil-
itate cell penetration [45,46]. Solutions of ﬁbrinogen/HA-ADH (1:1
by volume) were mixed with thrombin/HA-CHO-GRGDS (1:1 by
volume). Upon mixing, the two solutions formed a homogeneous
cross-linked hydrogel (ﬁbrin/HAX-GRGDS, the dermal component),
with a gelation time of 33 ± 3 s. The ﬁbrin/HAX-GRGDS gel adopted
the shape of the mold into which it was cast (Fig. 3A and B); byin-derived peptide sequence, GRGDS, and the peptide-modiﬁed HA-CHO-GRGDS (*
tide, corresponding to the asterisked peak at 2.6–2.8 ppm in panel B; § denotes the
10% the available carboxylic acids in HA were modiﬁed with the peptide (⁄ indicates
O-GRGDS conjugate relative to the molecular weight of HA-CHO.
Fig. 3. Dermal component. (A, B) The dermal component maintains the shape of the mold in which it was cast. (C, D) Viscoelastic shear properties of the different hydrogels.
(C) Elastic shear properties obtained by varying the frequency from 1 to 10 Hz. (D) The elastic shear modulus (G0) at 10 Hz. Data are means ± standard deviations, n = 4 for
each group, compared by an unpaired t-test (⁄⁄⁄p < 0.0001).
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ness and brittleness compared to the cross-linked gel (HAX).
Mechanical studies of the fully swollen gels (Fig. 3C and D) allowed
the calculation of the shear modulus (G) as 2413 ± 399 Pa for HAX-
GRGDS, 694 ± 93 Pa for ﬁbrin/HAX-GRGDS and 196 ± 34 Pa for
ﬁbrin. G has two components – storage (elastic) shear modulus
(G0) and loss (viscous) shear modulus (G0 0) – and is deﬁned by Eq.
(1):
G ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
G0  G0 þ G00  G00
p
ð1Þ
The G0 of fully swollen HAX-GRGDS-, ﬁbrin/HAX-GRGDS- and ﬁbrin
hydrogels was measured at 10 Hz, giving values of 2384 ± 404 Pa
for HAX-GRGDS, 694 ± 93 Pa for ﬁbrin/HAX-GRGDS and
193 ± 35 Pa for ﬁbrin. It has been reported that the matrix can actas a barrier to cells in 3-D culture at G0 higher than 1200 Pa, even
in the presence of protease-degradable elements or cell–integrin
binding sites [47]. The higher the G0, the more difﬁcult it is for ﬁbro-
blasts to spread, proliferate and migrate [47]. G can be correlated
with Young’s modulus according to Eq. (2) [48]:
E ¼ 2 G ð1þ vÞ ð2Þ
in which E is Young’s modulus, G is the shear modulus and v is Pois-
son’s ratio. A rough estimate of Emay be obtained from G by assum-
ing a Poisson’s ratio of 0.5 for a fully swollen hydrogel, such as the
ones reported here [49]. The calculated values of E for HAX-GRDS,
ﬁbrin/HAX-GRGDS and ﬁbrin were 7239 ± 1197, 2083 ± 279 and
587 ± 103 Pa, respectively. The values of E obtained for both the
ﬁbrin/HAX-GRGDS and the ﬁbrin hydrogel are within the range of
values for soft tissues in the human body [50]. The reduced stiffness
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cells to displace polymer chains and make room for their movement
[51]. The ﬁbrin gels were the softest, and were not elastic or stiff
enough to maintain their form during oscillatory shear mechanical
testing. In fact, low mechanical stiffness has been a limiting factor
for the use of scaffolds based solely on ﬁbrin and is a major reason
for its frequent combination with other scaffold materials [52].
Fibrin/HAX-GRGDS scaffolds with a diameter of 10 mm and a
thickness of 5 mm were prepared, containing 200,000 human der-
mal ﬁbroblasts per scaffold. Cells were suspended in the ﬁbrino-
gen/HA-ADH prior to mixing with thrombin/HA-CHO-GRGDS (1:1
by volume) to assure the homogeneous distribution of the cells
within the scaffold. The cells showed continuous proliferation over
9 days, as assessed by the alamarBlue assay [22] (Fig. 4A) and by
measuring the increase in the double-stranded DNA content [23]Fig. 4. Cell proliferation in the dermal substitute. (A) alamarBlue ﬂuorescence over time
each condition, compared by an unpaired t-test (⁄⁄⁄p < 0.0001). (C–F) Confocal ﬂuorescenc
points. Green (calcein-AM) and red (propidium iodine) stained cells are viable and dead(Fig. 4B). LIVE/DEAD staining and subsequent ﬂuorescence
microscopy demonstrated that the ﬁbroblasts were able to grow
three-dimensionally throughout the scaffold. Moreover, the negli-
gible number of dead cells indicated that the material had minimal
toxic effects on the cells. Twenty-four hours after seeding (day 1,
Fig. 4C), cells were alive and spherical; by day 3, they showed
the characteristic spindle shape of dermal ﬁbroblasts (Fig. 4D).
On days 6 (Fig. 4E) and 9 (Fig. 4F), ﬁbroblasts had proliferated
and spread extensively. Photomicrographs of the mid-portions of
H&E-stained horizontal sections of the dermal component con-
ﬁrmed that the ﬁbroblasts were distributed throughout (Fig. A1).
Cells cultured in HAX or ﬁbrin/HAX hydrogels without the GRGDS
modiﬁcation resulted in comparable numbers of calcein-stained
viable cells per scaffold (Fig. A2A and B), but the cells did not adopt
the characteristic spindle shape of ﬁbroblasts. Instead, ﬁbroblasts. (B) dsDNA concentration over time. Data are means ± standard deviations, n = 4 for
e images of dermal ﬁbroblasts growing in the dermal gel component at various time
, respectively.
Fig. 5. Epidermal component. (A) The epidermal component (HAX-PLL), held with one tine of a pair of forceps. (B) Young’s modulus of membranes, determined by atomic
force microscopy; note the log scale on the x-axis. The membranes were made of HAX or cross-linked HA with PLL (HAX-PLL, i.e. the epidermal component). Values are
means ± standard deviations, n = 4, compared by an unpaired t-test (⁄⁄⁄p < 0.0001).
Fig. 6. Cell growth on the laminin-coated epidermal component. (A) alamarBlue ﬂuorescence increased from day 1 to day 6. Values are means ± standard deviations, n = 4,
compared by an unpaired t-test (⁄p = 0.012; ⁄⁄p = 0.002). (B) LIVE/DEAD assay at day 3 showing healthy keratinocytes in green, with a typical cuboidal morphology. (C) Cell
staining showing cytokeratin-14 (green), a speciﬁc marker of epithelial basal keratinocytes at an early stage of differentiation. Phalloidin was used to stain actin ﬁlaments
(red). Nuclei were stained with DAPI (blue).
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HAX-GRGDS gels (in the absence of ﬁbrin), only sparse rounded
cells were observed (Fig. A2C), despite the presence of cell attach-
ment ligands. Previous reports [34,53] suggest that RGD-based cell
attachment ligands, protease-degradable elements and adequate
matrix stiffness all contribute to morphological changes, such as
acquiring a spindle shape and increased cell surface area [47].
Our ﬁndings are consistent with this view. Studies of degradation
in hyaluronidase showed that the hydrogel degraded over 11 days
(Fig. A3A–O).3.2. Epidermal component
The epidermal component was designed to deliver epidermal
keratinocytes to the wound site, allowing rapid re-epithelialization
of a full-thickness skin defect and protecting the dermal layer from
dehydration, mechanical disruption and infection. Dermal–epider-
mal interactions promote the proliferation of and the re-epithelial-
ization by keratinocytes [4]. Membranes (HAX-PLL) were obtained
by mixing 1 ml of PLL (1 mg ml1) into 2 ml of HA-CHO
(40 mg ml1) and then adding 2 ml of HA-ADH (40 mg ml1).
Hydrogel mixtures were left in polytetraﬂuoroethylene (Teﬂon)
molds overnight and were then cut into 8 mm diameter discs
(Fig. 5A). As shown by nanoindentation studies, the addition of
PLL signiﬁcantly increased the membranes’ Young’s moduli (E),
making them stiffer (Fig. 5B). Free-standing membranes of HA
(containing negatively charge carboxylic acids) and PLL (containing
negatively charged amines) have been produced by electrostatic
interaction between those polyelectrolytes [54]. To facilitate kerat-
inocyte attachment, one surface of the HA-PLL membrane wascoated with the most abundant component of the basement mem-
brane, the protein laminin-5 [55,56]. Membranes without that
coating showed very limited cell attachment (data not shown).
Keratinocytes on the laminin-coated membranes attached and pro-
liferated slowly, as assessed by the alamarBlue assay (Fig. 6A), for
the culture times of 1, 3 and 6 days. Fluorescence imaging of LIVE/
DEAD stained cells on those membranes showed that cells
attached and formed typical colonies (Fig. 6B) [57]. Confocal
images showed that keratinocytes expressed cytokeratin-14
(Fig. 6C), a keratin of the basal cells of all stratiﬁed squamous epi-
thelia [58], indicating that the keratinocytes were in an early stage
of differentiation, suitable for transplantation.3.3. Composite bilayer
To form a bilayer composite, the epidermal component was
placed on top of the dermal matrix immediately after its gelation.
The keratinocytes are only seeded on the top of the epidermal com-
ponent. The free aldehyde groups of the dermal hydrogel were
intended to react covalently with amines of the PLL-modiﬁed epi-
dermal HA membrane layer. This chemistry has been applied to
create glues which bind to tissue amines in situ [59,60] or to cross-
link cells with an aldehyde surface modiﬁcation to amines on
unmodiﬁed cells [61]. A piece of the composite with the approxi-
mate dimensions of 3 mm  5 mm  5 mm (H  L W) was cut
and imaged with the confocal microscope. Z-stacks performed at
different YX-positions of the sample showed a close apposition of
the two layers (i.e. the epidermal layer containing FITC-PLL (blue)
placed on the dermal component containing HA-CHO covalently
labeled with Alexa Fluor-647 (purple); see Section 2) (Fig. 7A).
Fig. 7. Combination of the dermal component with the epidermal component. (A)
Confocal ﬂuorescence image of the two-component system: the membrane is
labeled with FITC-PLL (blue) and the HA-CHO in the dermal component is
covalently labeled with Alexa Fluor-647 (purple). (B) SEM of the two-layered
system with the dense epidermal membrane on top and the more porous dermal
component on the bottom (arrows indicate the border between the epidermal and
the dermal components). (C) Load required to separate the dermal gel from the
epidermal membrane. HAX-PLL: adhesion force measured between an epidermal
component containing free amines and a dermal component containing aldehydes.
HAX only: adhesion force measured between an epidermal component without free
amines (PLL) and a dermal component containing aldehydes. HAX-PLL, ADH
blocking: conditions were as for HAX-PLL, but the aldehydes in the dermal
compartment were blocked with adipic dihydrazide. Values are means ± standard
deviations, n = 4, compared by an unpaired t-test (⁄⁄⁄p < 0.0001).
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two layers: a dense epidermal HAX-PLL membrane on top of a por-
ous dermal scaffold (Fig. 7B). The small pore size (17.58 ± 6.49 lm)
and ﬂat surface of the epidermal component was designed to allow
the formation of a cell monolayer with no cellular ingrowth, whileallowing the diffusion of small molecules. The considerably bigger
pores (177.49 ± 93.03 lm) of the dermal layer as well as the
admixture of proteolytically degradable ﬁbrin were designed to
allow dermal ﬁbroblasts to spread into the scaffold in three dimen-
sions (Fig. 4C–F).
Mechanical testing (Fig. 7C) showed that a maximal force of
0.094 ± 0.006 N was necessary to detach the epidermal membrane
made of HA and PLL from the dermal substitute, whereas only
0.036 ± 0.001 N was required for an epidermal membrane made
of HA with no free amines. Capping of the free aldehydes in the
dermal component with adipic acid dihydrazide prior to the
mechanical testing resulted in values (0.021 ± 0.007 N) similar to
those obtained with the membrane lacking free amines. These
results suggest that the amine–aldehyde reaction created strong
imine bonds between the two parts of the composite scaffold. This
chemistry has been used to crosslink cells with an aldehyde surface
modiﬁcation to amines on unmodiﬁed cells [61], to create glues
which bind to tissue amines in situ [20,21] and to enable in situ
crosslinking hydrogels to be used in the peritoneum, without any
toxic effects [40,62,63]. These tissue glues based on an aldehyde-
modiﬁed dextran which reacts with free amines on the cell surface
have approximately twice the adhesion strength of our system
[64]. This may be because some of the aldehyde groups in our der-
mal system have reacted with the hydrazide-modiﬁed HA to form
HAX-GRGDS and are not available for reaction with the PLL amines
of the epidermal compartment.
Our approach offers a number of advantages over the current
available skin substitutes: it uses materials that are approved for
other applications by the Food and Drug Administration; it can
be produced at an adequate cost and by reproducible methods;
and it promotes angiogenesis (ﬁbrin [15–17] and hyaluronic acid
[18]).4. Conclusion
We have developed a composite scaffold that combines a ﬁbro-
blast-containing dermal matrix with a keratinocyte-containing
epidermal membrane, linked together by amine–aldehyde interac-
tions. Due to its in situ cross-linking ability, the dermal gel compo-
nent is easy to apply and will conform to the shape of any lesion.
The dermal component has the appropriate mechanical properties,
cell adhesion sites and protease-degradable elements to allow the
tridimensional spreading of human ﬁbroblasts, forming a dermal
matrix. The epidermal component is robust and allows the creation
of a monolayer of keratinocytes. It will protect the dermal matrix
from dehydration and infection. The composite bilayer described
here holds potential as a skin replacement product that would
allow establishment of both skin layers in a single procedure.Notes
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Certain ﬁgures in this article, particularly Figures 1 and 3–7 are
difﬁcult to interpret in black and white. The full colour images can
be found in the on-line version, at http://dx.doi.org/10.1016/
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